Published: Tue, October 10, 2017
Medicine | By Brett Sutton

Flexion Therapeutics (FLXN) Earns Daily Media Sentiment Rating of

Flexion Therapeutics (FLXN) Earns Daily Media Sentiment Rating of

Over the last three months, the shares of the company have changed 40.98% and performed 13.29% over the last six months.

A number of other research analysts have also recently commented on the company. ValuEngine upgraded shares of Flexion Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, September 1st.

On August 24 analysts at Northland Securities started coverage with an initial rating of "Outperform".

Analysts have given a mean recommendation of 2.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Based on the latest brokerage notes which have been released to investors, 4 brokers have issued a rating of "strong buy", 4 brokers "buy", 0 brokers "neutral", 0 brokers "sell" and 0 brokers "strong sell". Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. 1064156 shares were traded on Flexion Therapeutics Inc's last session. Higher relative volume you will have more liquidity in the stock which will tighten spreads and allow you to trade with more size without a ton of slippage. (NASDAQ:FLXN) was gathering the crowd in the stock market. The stock's 50-day moving average is $22.93 and its 200-day moving average is $20.52. Flexion Therapeutics has a 12 month low of $15.93 and a 12 month high of $32.25.


Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 8th. Previously Flexion Therapeutics (NASDAQ:FLXN) reported $-0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.82 by $-0.09 with surprise factor of -11%.

03/10/2015 - Flexion Therapeutics Inc was downgraded to "neutral" by analysts at Zacks. "(FLXN) PT Raised to $37.00 at BMO Capital Markets" was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of USA & global copyright and trademark law.

The good news is there's still room for Flexion Therapeutics, Inc. A total of 8.21 million shares exchanged at hands and its average trading volume is standing at 0.67 million shares. Following the acquisition, the insider now directly owns 5,000 shares of the company's stock, valued at $120,750. ProShare Advisors LLC grew its holdings in shares of Flexion Therapeutics by 5.5% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company's stock valued at $1,284,000 after purchasing an additional 7,667 shares during the period. Public Employees Retirement System of OH now owns 41,644 shares of the specialty pharmaceutical company's stock worth $842,000 after buying an additional 17,066 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Flexion Therapeutics by 3.9% during the 2nd quarter. Its minimum price target estimates has been figured out at $35 while the maximum price target forecast is established at $44. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company's stock valued at $2,047,000 after purchasing an additional 513 shares during the last quarter. The original version of this story can be viewed at https://weekherald.com/2017/10/10/janney-montgomery-scott-boosts-flexion-therapeutics-inc-flxn-price-target-to-570-00.html. Institutional investors and hedge funds own 83.26% of the company's stock.

For the past 5 years, Flexion Therapeutics, Inc.'s EPS growth has been almost -29.6%. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. (FLXN) announced that the FDA has approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain.

Like this: